Recent Advancement and Technological Aspects of Pulsatile Drug Delivery System - A Laconic Review

Pandit, Vinay; Kumar, Ajay; Ashawat, Mahendra Singh; Verma, Chander P; Kumar, Pravin

doi:10.2174/1389450117666160208144343

Cited by 14 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the advance of bionanotechnology, drug delivery scientists launched several innovative drug delivery systems to satisfy various clinical situations [ 5 ]: 1) the pulsatile drug delivery systems (PDDS) [ 6 ]; 2) dynamic nanoassembly-based drug delivery systems (DNDDS) [ 7 ]; and, 3) long-acting drug delivery systems (LADDS) [ 8 ].…”

Section: Evolution Of Drug Delivery Sciencementioning

confidence: 99%

Potential next-generation medications for self-administered platforms

Chen

Cheng

2022

Journal of Controlled Release

View full text Add to dashboard Cite

Section: Evolution Of Drug Delivery Sciencementioning

confidence: 99%

Potential next-generation medications for self-administered platforms

Chen

Cheng

2022

Journal of Controlled Release

View full text Add to dashboard Cite

“…Body biological process and functions are organized in the time of 24 h to conduct specific activity in particular time. Numbers of diseases are following the biological rhythm (table 5) [35,36].…”

Section: Disease That Required Pulsatile Drug Delivery Systemmentioning

confidence: 99%

“…At present, technology developing rate is high which is helpful for performing the experiments in large number with easy way and in less time. Thus, numbers of experiments were performed and numbers of formulation are developed with high efficacy, bioavailability, stability and low risks [35][36][37][38]42].…”

Section: Recent Advancement In Pulsatile Drug Delivery Systemmentioning

confidence: 99%

See 1 more Smart Citation

A Review on Recent Advancement in Pulsatile Drug Delivery Systems

Thakur¹,

Wani²,

Gautam³

2021

Int J Curr Pharm Sci

View full text Add to dashboard Cite

Delivery systems with a pulsatile-release method are particularly involved in designing medicines for which traditional managed drug-release systems with the continuous release are not suitable. This medication also has a high first-pass impact or special conditions for chrono-pharmacology. These medications also have a high first-pass or unique chronopharmacological effect. The pulsatile release profile is characterised by a duration of no release (lag time) followed by a fast and full release of the drug. Pulsatile drug delivery systems may be classified into site-specific systems in which the drug is released inside the gastrointestinal system (e. g. colon) or time-controlled devices wherein the drug is released after a well-defined time period. Site-regulated release is typically controlled by environmental factors, such as pH or enzymes found in the intestinal tract, whereas drug release from time-controlled processes is controlled mainly by the delivery system and, preferably, not by the environment. This review covers various single-and multiple-unit oral pulsatile drug-delivery systems with an emphasis on time-controlled drug-release systems.

show abstract

“…Drug delivery systems, such as hot melt extrusion, solventcasting, and soaking the polymers into a drug solution, are traditional drug delivery systems. It contains numerous limitations, such as bad drug control release, lack of targeting, poor water solubility, and susceptibility to drug resistance (Tiwari et al, 2012;Edgar and Wang, 2017;Pandit et al, 2017). Lim et al (2018) designed a bilayer swellable drug-eluting ureteral stent used for treating urothelial diseases.…”

Section: Traditional Drug Delivery Systemsmentioning

confidence: 99%

Advances in Drug Delivery via Biodegradable Ureteral Stent for the Treatment of Upper Tract Urothelial Carcinoma

et al. 2020

View full text Add to dashboard Cite

Drug eluting ureteral stent is an effective means for local drug delivery to the urinary tract. It can potentially solve a variety of upper urinary tract problems, such as stent-related urinary tract infections and discomfort, ureteral stricture, and neoplastic diseases. However, the release of drug elutes on the surface of biostable stents is unsustainable and uncontrollable. With the development of biomaterial science, the emergence of biodegradable ureteral stents (BUSs) provides a new approach for local drug delivery in the urinary tract. The drugs can be continuously released in a controlled manner from a drug-eluting BUS, when the stent degrades. Especially for the delivery of anti-tumor drugs, the stents can obviously improve the therapeutic effectiveness of the drugs by prolonging the contact duration of the drug and tumor cells. In addition, a secondary stent removal procedure can be avoided. The purpose of this review article is to provide an overview of anti-tumor drug-eluting BUSs and discuss the biomaterials and drug delivery systems of BUS that are currently being developed to deliver anti-tumor drugs for upper tract urothelial carcinoma.

show abstract

Recent Advancement and Technological Aspects of Pulsatile Drug Delivery System - A Laconic Review

Abstract: Pulsatile medication possess the potential to deliver the drugs in the therapy of diseases where drug dose is essential during sleep, drugs having greater first pass metabolism and absorption at precise location in digestive tract.

Cited by 14 publications

References 0 publications

Potential next-generation medications for self-administered platforms

Potential next-generation medications for self-administered platforms

A Review on Recent Advancement in Pulsatile Drug Delivery Systems

Advances in Drug Delivery via Biodegradable Ureteral Stent for the Treatment of Upper Tract Urothelial Carcinoma

Contact Info

Product

Resources

About